ICG administration
Phase 1Small molecule
ICG administration is one of 28 small molecule programs targeting Surgery. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
33 competitors in Surgery
#DrugCompanyPhaseTrials
1Alfenta
Jazz PharmaceuticalsApproved
Journavx
Vertex PharmaceuticalsApproved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Levophed
GGeneral Hospital of Ningxia Medical University
Approved
Nubain
AAultman Health Foundation
Approved
Desferal
Jazz PharmaceuticalsPhase 3
Cardene
Sun Pharmaceutical Industries, Inc.Phase 2
Tukysa
PfizerPhase 2
Senna
MMedtronic - MITG
Phase 3
Inlyta
PPrism Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Surgery1 trial
NIFR Image-guided Surgery for Malignant Soft Tissue Tumor With Low-dose SWIG Technique
Not yet recruiting·TThe Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College·Phase 1·NCT06610071·592 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ICG administration. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details